Afatinib Monotherapy
Indication
00221a
Treatment of EGFR TKI- naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s).
Alectinib Monotherapy
Indication
00401a
Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
00401b
As monotherapy is indicated for the first-line treatment of adultpatients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
00401c
As monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with anaplastic lymphoma kinase (ALK)‑positive NSCLC at high risk of recurrence.
Atezolizumab Monotherapy- 21 day
Indication
00544a
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.
00544d
As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC
00544e
Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on ≥50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations
00544f
For the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), where this is a continuation of treatment for patients who have completed the induction chemotherapy component of the treatment
Atezolizumab 1680mg Monotherapy – 28 Day
Indication
00593a
Treatment of adult patients with locally advanced or metastatic nonsmall
cell lung cancer (NSCLC) after prior chemotherapy.
00593d
As monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC
00593e
For the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), where this is a continuation of treatment for patients who have completed the induction chemotherapy component of the treatment
00593f
Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on ≥50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations.
Atezolizumab 840mg Monotherapy – 14 day
Indication
00592d
As monotherapy for the first-line treatment of adult patients with
metastatic non-small cell lung cancer (NSCLC) whose tumours have a PDL1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating
immune cells (IC) and who do not have EGFR mutant or ALK-positive
NSCLC.
00592e
Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on ≥50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations.
00592f
For the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), where this is a continuation of treatment for patients who have completed the induction chemotherapy component of the treatment
Bevacizumab 7.5 mg/kg –21 days
Indication
00214b
In addition to platinum-based chemotherapy is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.
Atezolizumab 1200mg, CARBOplatin AUC 5 and Etoposide 100mg/m2 Therapy
Indication
00689a
First-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Bevacizumab 15 mg/kg –21 days
Indication
00215f
In addition to platinum-based chemotherapy is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.
00215g
In combination with erlotinib is indicated for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous cell lung cancer with Epidermal Growth Factor (EGFR) activating mutations.
Brigatinib Therapy
Indication
00562a
For the treatment of adult patients with anaplastic lymphoma kinase(ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
00562b
Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor
CARBOplatin (AUC5) and Etoposide 100mg/m2Therapy-21 days
CARBOplatin (AUC 3), Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day
Indication
00561a
Stage III Non Small cell lung cancer (NSCLC) in patients not suitable for treatment with CISplatin
CARBOplatin and Oral Etoposide Therapy-21 days
CARBOplatin (AUC6) and PACLitaxel 200mg/m2 Therapy
Indication
00304a
Adjuvant Treatment of Stage I,II and IIIA Non Small Cell Lung Cancer( NSCLC)*
00304b
Treatment of locally advanced, recurrent or metastatic NSCLC*00304c
In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%
CARBOplatin and Vinorelbine Therapy-21 Day
Indication
00614a
Treatment of locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC) in patients not suitable for treatment with CISplatin
Ceritinib Monotherapy
Indication
00340a
Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.
CISplatin (50mg/m2) and Etoposide (50mg/m2) and Thoracic Radiotherapy (TRT) -28 day
CISplatin and Etoposide
CISplatin (75mg/m2) + Etoposide (100mg/m2) + Radiotherapy (RT) - 21 day
Crizotinib Monotherapy
Indication
00243a
Treatment of adults with previously treated ALK-positive advanced NSCLC
00243b
The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)
00243c
First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
Dacomitinib Monotherapy
Indication
00565a
Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations
Durvalumab Monotherapy 10mg/kg – 14 Day
Indication
00576a
As monotherapy is indicated for the treatment of locally advanced, unresectable NSCLC in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT)
Durvalumab Monotherapy 1500mg – 28 Day
Indication
00655a
As monotherapy is indicated for the treatment of locally advanced, unresectable NSCLC in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT)
DOCEtaxel Monotherapy 75mg/m2 – 21 day cycle
Indication
00203a
Treatment of locally advanced or metastatic NSLC after failure of prior chemotherapy
Entrectinib Monotherapy – Adult
Indication
00702a
As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
Erlotinib Monotherapy
Indication
00219a
First-line treatment of patients with locally advanced or metastatic non- small cell lung cancer (NSCLC) with EGFR activating mutations.
00219b
Switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy.
00219c
Treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
Gefitinib Monotherapy
Indication
00220a
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK
Gemcitabine (1000mg/m2) and CARBOplatin (AUC5) Therapy-21 day
Indication
00310b
Treatment of patients with locally advanced, recurrent or metastatic non small cell lung cancer (NSCLC)
00310c
In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%
Gemcitabine (1250mg/m2) and CISplatin 75mg/m2Therapy-21day
Indication
00281a
Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
00281b
In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%
Gemcitabine 1000mg/m2Monotherapy- 28 day
Indication
00284b
Treatment of elderly patients or patients with ECOG =2 with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Lorlatinib Therapy
Indication
00570a
As monotherapy for the treatment of adult patients with anaplasticlymphoma kinase (ALK)-positive advanced non-small cell lung cancer(NSCLC), following disease progression on
(i) alectinib or ceritinib as the first ALK-targeted treatment
or
(ii) crizotinib and at least one other ALK-targeted treatment
Lorlatinib Therapy
Indication
00570b
As monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously not treated with an ALK inhibitor
Intravenous Vinorelbine Therapy-21 days
Nintedanib Therapy
Indication
00372a
Treatment of adult patients with locally advanced, metastatic of stage IIIB or IV, or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy
Nivolumab 360mg and Chemotherapy
Indication
00849a
Nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%
Nivolumab Monotherapy - 14 day
Indication
00483e
As monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.
Nivolumab Monotherapy - 28 day
Indication
00484f
As monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.
Nivolumab 360mg and Ipilimumab 1mg/kg Therapy
Indication
00792a
Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma
Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy
Indication
00712a
First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.
Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy
Indication
00713a
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.
Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy
Indication
00714a
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitising EGFR mutation or ALK translocation.
Oral Etoposide Therapy
Indication
00388a
Small cell lung cancer (SCLC) extensive disease in patients unsuitable for intravenous or combination chemotherapy.
Oral Vinorelbine Monotherapy 7 days
Osimertinib Monotherapy
Indication
00353a
Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
00353b
First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
00353c
As monotherapy for adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) whose tumour has epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.
PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day
PACLitaxel 80mg/m2 Day 1, 8, 15 Monotherapy-28 Day
Pembrolizumab 200mg Monotherapy
Indication
00455a
First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.
00455n
As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at a high risk of recurrence following complete resection and platinum-based chemotherapy
Pembrolizumab 400 mg monotherapy
Indication
00558a
First-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR mutations or ALK translocations.
00558n
As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at a high risk of recurrence following complete resection and platinum-based chemotherapy
Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy
Indication
00568a
Pembrolizumab is indicated in combination with PEMEtrexed and CARBOplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations
Pembrolizumab, PEMEtrexed and CISplatin Therapy
Indication
00569a
Pembrolizumab is indicated in combination with PEMEtrexed and CISplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations
Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) Therapy
Indication
00579a
Pembrolizumab In Combination with CARBOplatin and PACLitaxel for the first-line treatment of Patients with metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
PEMEtrexed and CARBOplatin Therapy
Indication
00318a
Treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
00318b
First line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology.
00318c
In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%
PEMEtrexed and CISplatin Therapy
Indication
00317a
Treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
00317b
First line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
00317c
In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%
PEMEtrexed Monotherapy
Indication
00222a
Maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients who disease has not progressed immediately following platinum-based chemotherapy.
00222b
Second line treatment of patients with locally advanced or metastatic NSLC other than predominantly squamous cell histology.
Serplulimab, CARBOplatin AUC5 and Etoposide 100mg/m2 – 21 Day Therapy
Indication
00908a
In combination with CARBOplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Tepotinib Therapy
Indication
00823a
As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy
Topotecan Monotherapy-5 day
Indication
00311b
Treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.
Topotecan Oral Monotherapy
Indication
00587a
Treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first –line regimen is not considered appropriate
Vinorelbine 30 (Day 1, 8, 15) and CISplatin 80 (Day 1) Therapy-21 day
Indication
00339a
Adjuvant treatment of patients with completely resected stage IB, ll or lllA non small cell lung cancer (NSLC).
00339b
Treatment of locally advanced recurrent or metastatic NSCLC.
Vinorelbine and CISplatin Therapy-28 days
Indication
00339a
Adjuvant treatment of patients with completely resected stage IB, ll or lllA non small cell lung cancer (NSLC).
00339b
Treatment of locally advanced recurrent or metastatic NSCLC.
Vinorelbine and CISplatin Therapy-28 days
Indication
00343a
Adjuvant treatment of patients with completely resected stage IB, ll or lllA non small cell lung cancer (NSLC).
00343b
Treatment of locally advanced recurrent or metastatic NSCLC.